Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
01-03-2006
REPORT TYPE
Annual Summary
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERStanford University Stanford, CA 94305
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTThis study was designed to identify new, mechanistically relevant biomarkers of selenium responsiveness for use in intervention trials. We have characterized the global transcriptional response of LNCaP prostate cancer cells to selenium by using cDNA microarray. We have identified molecular targets of selenium that are secretory using bioinformatics approaches and datasets of selenium modulated transcripts and membrane bound and secretory proteins. To help prioritizing biomarker candidates, we have cross-referenced the selenium modulated genes list with existing prostate cancer microarray data sets. Using this approach, we have narrowed down the number of biomarker candidates that we are now characterizing in more details. Introduction Biomarkers of selenium actions in prostate tissue would be of great value in stratifying patients and monitoring the study subject compliance in clinical trials. We hypothesized that a subset of genes that show expression changes after selenium supplementation encode secretory proteins that can be detected in serum and serve as biomarkers of response to selenium. To identify such biomarkers, we proposed to identify molecular targets of selenium that are secretory using bioinformatics approaches and datasets of selenium modulated transcripts and membrane bound and secretory proteins.
SUBJECT TERMSBody Methylseleninic acid (MSA) has been shown to have potent anticancer activity and is an excellent compound for studying the anticancer effect of selenium in vitro. The global transcriptional response ...